<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">101311472</journal-id>
<journal-id journal-id-type="pubmed-jr-id">34100</journal-id>
<journal-id journal-id-type="nlm-ta">Cell Stem Cell</journal-id>
<journal-id journal-id-type="iso-abbrev">Cell Stem Cell</journal-id>
<journal-title-group>
<journal-title>Cell stem cell</journal-title>
</journal-title-group>
<issn pub-type="ppub">1934-5909</issn>
<issn pub-type="epub">1875-9777</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28803918</article-id>
<article-id pub-id-type="pmc">5591075</article-id>
<article-id pub-id-type="doi">10.1016/j.stem.2017.07.009</article-id>
<article-id pub-id-type="manuscript">NIHMS894184</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Modeling of TREX1-dependent autoimmune disease using human stem cells
highlights L1 accumulation as a source of neuroinflammation</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Thomas</surname>
<given-names>Charles A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN2">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tejwani</surname>
<given-names>Leon</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="author-notes" rid="FN2">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Trujillo</surname>
<given-names>Cleber A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Negraes</surname>
<given-names>Priscilla D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Herai</surname>
<given-names>Roberto H.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mesci</surname>
<given-names>Pinar</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Macia</surname>
<given-names>Angela</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Crow</surname>
<given-names>Yanick J.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Muotri</surname>
<given-names>Alysson R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="author-notes" rid="FN3">7</xref>
<xref ref-type="author-notes" rid="FN1">*</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>University of California San Diego, School of Medicine, Department
of Pediatrics/Rady Children’s Hospital San Diego, Department of Cellular
&amp; Molecular Medicine, Kavli Institute for Brain and Mind, Stem Cell Program,
Center for Academic Research and Training in Anthropogeny (CARTA), La Jolla, CA
92037-0695, USA</aff>
<aff id="A2">
<label>2</label>Yale University, Interdepartmental Neuroscience Program, New Haven,
CT 06510, USA</aff>
<aff id="A3">
<label>3</label>Pontifícia Universidade Católica do Paraná,
School of Medicine, Graduate Program in Health Sciences, Curitiba, Paraná,
Brazil</aff>
<aff id="A4">
<label>4</label>INSERM UMR 1163, Laboratory of Neurogenetics and Neuroinflammation,
Paris Descartes – Sorbonne Paris Cité University, Institut Imagine,
Hôpital Necker, Paris, France</aff>
<aff id="A5">
<label>5</label>University of Manchester, Medical and Human Sciences, Manchester
Academic Health Sciences Centre, UK</aff>
<author-notes>
<corresp id="FN1"><label>*</label>To whom correspondence should be addressed: Dr. Alysson
R. Muotri, 2880 Torrey Pines Scenic Drive, La Jolla, CA 92093-0695,
<email>muotri@ucsd.edu</email>, Phone: (858) 534-9320</corresp>
<fn id="FN2">
<label>6</label>
<p>These authors contributed equally</p>
</fn>
<fn id="FN3">
<label>7</label>
<p>Lead contact</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>19</day>
<month>7</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>10</day>
<month>8</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<day>07</day>
<month>9</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>07</day>
<month>9</month>
<year>2018</year>
</pub-date>
<volume>21</volume>
<issue>3</issue>
<fpage>319</fpage>
<lpage>331.e8</lpage>
<!--elocation-id from pubmed: 10.1016/j.stem.2017.07.009-->
<abstract id="Abs1">
<title>Summary</title>
<p id="P3">Three-prime repair exonuclease I (TREX1) is an anti-viral enzyme that
cleaves nucleic acids in the cytosol, preventing accumulation and a subsequent
type-I interferon-associated inflammatory response. Autoimmune diseases,
including Aicardi-Goutières syndrome (AGS) and systemic lupus
erythematosus, can arise when TREX1 function is compromised. AGS is a
neuroinflammatory disorder with severe and persistent intellectual and physical
problems. Here, we generated a human AGS model that recapitulates
disease-relevant phenotypes using pluripotent stem cells lacking TREX1. We
observed abundant extrachromosomal DNA in TREX1-deficient neural cells, of which
endogenous Long Interspersed Element-1 retrotransposons were a major source.
TREX1-deficient neurons also exhibited increased apoptosis and formed
three-dimensional cortical organoids of reduced size. TREX1-deficient astrocytes
further contributed to the observed neurotoxicity through increased type-I
interferon secretion. In this model, reverse transcriptase inhibitors rescued
the neurotoxicity of AGS neurons and organoids, highlighting their potential
utility in therapeutic regimens for AGS and related disorders.</p>
</abstract>
<abstract abstract-type="graphical" id="Abs2">
<title>eTOC Blurb</title>
<p id="P1">Thomas, Tejwani et al. used human pluripotent stem cells to dissect the
contribution of neurons and glia to the neuroinflammatory disorder
Aicardi-Goutières syndrome (AGS). They found that mutant cells
accumulate retroviral-like extrachromosomal nucleic acids that trigger a
neurotoxic response, and suggest that anti-retrovirals could potentially provide
therapy for this disease.</p>
<p id="P2">
<graphic orientation="portrait" position="anchor" xlink:href="nihms894184u1.jpg"></graphic></p>
</abstract>
<kwd-group>
<kwd>Disease modeling</kwd>
<kwd>TREX1</kwd>
<kwd>neuroinflammation</kwd>
<kwd>Aicardi-Goutières syndrome</kwd>
<kwd>LINE-1</kwd>
<kwd>Type-I IFN</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>